Epigenomics' Colorectal Cancer Test Approved in Argentina | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics and VSA Alta Complejidad today announced that VSA has been approved to market Epigenomics' Epi proColon kit in Argentina.

The companies have worked together since last year to secure regulatory approval for Epigenomics' blood-based colorectal cancer test from ANMAT, which regulates diagnostic tests in Argentina. They also said that VSA has forged relationships with leading diagnostic reference laboratories in Argentina to make Epi proColon available there.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.